Commentary

Video

Dr. Tyson shares interim findings from the BOND-003 trial in NMIBC

Author(s):

Urology Times staff
Conference|AUA

Mark D. Tyson, II, MD, MPH, shares interim findings from the BOND-003 trial, evaluating cretostimogene grenadenorepvec in patients with high risk, papillary only, BCG-unresponsive non–muscle-invasive bladder cancer.

In this video, Mark D. Tyson, II, MD, MPH, shares the background and key findings from the study, “BOND-003- Cohort P: A Multi-national, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, Papillary Only, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer,” which was presented at the 2024 American Urological Association Annual Meeting in San Antonio, Texas. Tyson is a urologic oncologist at Mayo Clinic in Phoenix, Arizona.

Related Videos
Helen L. Bernie, DO, MPH, answers a question during a Zoom video interview
Colin Goudelocke, MD, answers a question during a Zoom video interview
Prostate cancer cells dividing | Image Credit: © PRB ARTS - stock.adobe.com
Amy E. Krambeck, MD, answers a question during a Zoom video interview
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
Shot of a doctor showing a patient some information on a digital tablet | Image Credit: © bongkarn - stock.adobe.com
Related Content
CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC
February 20th 2025

CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC

Thomas E. Hutson, DO, PharmD
"The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC
February 18th 2025

Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC

Hannah Clarke
However, the triplet regimen did not lead to an improvement in overall survival.
blurred photo of a clinic hallway
May 28th 2023

2023 AUA highlights in benign urology

Urology Times staff
Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
Urinary bladder cancer | Image Credit: © Matthieu - stock.adobe.com
February 16th 2025

Disitamab vedotin plus toripalimab shows safety, efficacy in MIBC

Benjamin P. Saylor
"The results [indicate] that neoadjuvant DV combined with toripalimab had promising efficacy and acceptable safety in patients with HER2-expressing MIBC,” said Xinan Sheng, MD.
Human kidney cross section on scientific background | Image Credit: © Crystal light - stock.adobe.com
February 15th 2025

Latest LITESPARK-003 data highlight antitumor activity of belzutifan plus cabozantinib

Benjamin P. Saylor
ORR was 70% (95% CI, 55-82) in cohort 1 compared with 31% (95% CI, 19-45) in cohort 2.
© 2025 MJH Life Sciences

All rights reserved.